Year-End Report

WILLIAMS AND JENSEN, PLLC for ASTRAZENECA PHARMACEUTICALS LP (FORMERLY ASTRAZENECA PHARMACEUTICALS GROUP)

Firm
Client
Income
$100,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare drug benefit; Medicaid drug rebate; drug price negotiation.

LobbyistCovered position, as disclosed
JENNY DIJAMES N/A
DAVID E FRANASIAK N/A
JACK STEVEN HART N/A
CHRISTOPHER W HATCHER N/A
SUSAN HIRSCHMANN N/A
KARINA LYNCH N/A
GEORGE OLSEN N/A
JOEL OSWALD N/A

Contacted: White House Office; SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Tax issues affecting the drug industry; CFIUS.

LobbyistCovered position, as disclosed
JENNY DIJAMES N/A
DAVID E FRANASIAK N/A
JACK STEVEN HART N/A
CHRISTOPHER W HATCHER N/A
SUSAN HIRSCHMANN N/A
KARINA LYNCH N/A
GEORGE OLSEN N/A
JOEL OSWALD N/A

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office

Health Issues HCR

Drug importation and counterfeiting; pediatric trials and studies; drug safety/clinical trials; Follow-On biolgoics; drug advertising; comparative effectiveness; mental health parity; prescription drug user fees; drug payment disclosure legislation; S. 2029.

LobbyistCovered position, as disclosed
JENNY DIJAMES N/A
DAVID E FRANASIAK N/A
JACK STEVEN HART N/A
CHRISTOPHER W HATCHER N/A
SUSAN HIRSCHMANN N/A
KARINA LYNCH N/A
GEORGE OLSEN N/A
JOEL OSWALD N/A

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office

Bills named: S. 2029 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.